

SUBJECT: Naloxone Availability

SUBMITTED BY: Gregory R. Turissini OMS-II, OU-HCOM, Vincent Pan OMS-III, TUNCOM  
Shikha Patel, OMS- II, RowanSOM  
Michigan Association of Osteopathic Family Physicians (MAOFP)

REFERRED TO: 2019 ACOFP Congress of Delegates

---

RESOLUTION NO. 21

- 1 WHEREAS, overdoses from both illicit and prescription opioids has increased almost 600% since  
2 1999; and  
3
- 4 WHEREAS, opioid overdoses have killed more than 47,000 Americans in 2017, 67.8% of all drug  
5 overdose deaths involved opioids, and 36% of those deaths involved prescription opioids; and  
6
- 7 WHEREAS, competitive opioid receptor antagonists, such as naloxone, are safe to use and are  
8 recommended in the immediate treatment of opioid overdose; and  
9
- 10 WHEREAS, naloxone is available without a prescription in 48 states, and is being administered by  
11 emergency medical services (EMS) and pharmacy staff; and  
12
- 13 WHEREAS, there are varying state laws and also a large variation in the availability and administration  
14 of naloxone among health care providers and establishments; and  
15
- 16 WHEREAS, osteopathic family physicians can play a vital role in the advocacy of increased affordability  
17 and access to naloxone in both rural and urban communities; now, therefore be it  
18
- 19 RESOLVED, that the American College of Osteopathic Family Physicians (ACOFP) support an increase  
20 in public availability and use of naloxone.

References:

<https://osteopathic.org/about/leadership/policy-search/?aoatextsearchinline=naloxone>  
<https://www.cvs.com/content/prescription-drug-abuse/save-a-life>  
<https://www.cdc.gov/drugoverdose/data/index.html>

FINAL ACTION: APPROVED as of March 21, 2019